{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:24:21Z","timestamp":1787963061972,"version":"build-2784847793"},"reference-count":45,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T00:00:00Z","timestamp":1723075200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"S.C. KOMTUR PHARMACEUTICALS S.R.L","award":["25\/26 May 2022"],"award-info":[{"award-number":["25\/26 May 2022"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Resistance to first-generation somatostatin receptor ligand (fgSRL) treatment in acromegaly is common, making the identification of biomarkers that predict fgSRL response a desired goal. We conducted a retrospective analysis on 21 patients with acromegaly who underwent surgery and subsequent pharmacological treatment. Through immunohistochemistry (IHC), we assessed the expression of the somatostatin receptor subtypes SSTR2 and SSTR5, E-Cadherin, and cytokeratin granulation pattern (sparsely or densely). Patients were divided into responders and non-responders based on their biochemical response to fgSRL and\/or the newer agent, Pasireotide, or the GH-blocker, Pegvisomant. Patients resistant to fgSRL (n = 12) exhibited lower SSTR2 and E-Cadherin expressions. Sparsely granulated tumors were more frequent in the non-responder group. SSTR2 (p = 0.024, r = 0.49) and E-Cadherin (p = 0.009, r = 0.64) positively correlated with the Insulin-like Growth Factor 1 (IGF-1) decrease after fgSRL, while SSTR5 (p = 0.107, r = \u22120.37) showed a trend towards negative correlation. SSTR5 positivity seemed to be associated with Pasireotide response, albeit the number of treated patients was too low (n = 4). No IHC markers correlated with Pegvisomant response. Our findings suggest that densely granulated tumors, with positive SSTR2 and E-Cadherin seem to be associated with favorable fgSRL responses. The strongest predictive value of the studied markers was found for E-Cadherin, which seems to surpass even SSTR2.<\/jats:p>","DOI":"10.3390\/ijms25168663","type":"journal-article","created":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T15:04:24Z","timestamp":1723129464000},"page":"8663","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Predicting Response to Medical Treatment in Acromegaly via Granulation Pattern, Expression of Somatostatin Receptors Type 2 and 5 and E-Cadherin"],"prefix":"10.3390","volume":"25","author":[{"given":"Maximilian Cosma","family":"Gliga","sequence":"first","affiliation":[{"name":"Doctoral School of Medicine and Pharmacy, George Emil Palade University of Medicine, Pharmacy, Sciences and Technology of Targu Mures, 540142 Targu Mures, Romania"},{"name":"Department of Endocrinology, George Emil Palade University of Medicine, Pharmacy, Sciences and Technology of Targu Mures, 540142 Targu Mures, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Chinezu","sequence":"additional","affiliation":[{"name":"Department of Histology, George Emil Palade University of Medicine, Pharmacy, Sciences and Technology of Targu Mures, 540142 Targu Mures, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ionela Maria","family":"Pascanu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, George Emil Palade University of Medicine, Pharmacy, Sciences and Technology of Targu Mures, 540142 Targu Mures, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,8,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.mayocp.2021.11.007","article-title":"Diagnosis and Treatment of Acromegaly: An Update","volume":"97","author":"Ershadinia","year":"2022","journal-title":"Mayo Clin. Proc."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"630","DOI":"10.20945\/2359-3997000000193","article-title":"Determinants of morbidities and mortality in acromegaly","volume":"63","author":"Kasuki","year":"2019","journal-title":"Arch. Endocrinol. Metab."},{"key":"ref_3","first-page":"519","article-title":"Acromegaly treatment in Romania. How close are we to disease control?","volume":"68","author":"Niculescu","year":"2017","journal-title":"Endokrynol. Pol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11102-020-01091-7","article-title":"A Pituitary Society update to acromegaly management guidelines","volume":"24","author":"Fleseriu","year":"2021","journal-title":"Pituitary"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s11102-017-0791-0","article-title":"Somatostatin receptor ligands in the treatment of acromegaly","volume":"20","author":"Gadelha","year":"2017","journal-title":"Pituitary"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e4567","DOI":"10.1210\/clinem\/dgaa664","article-title":"Surgical and pharmacological outcomes in acromegaly: Real-life data from the mexican acromegaly registry","volume":"105","author":"Mercado","year":"2020","journal-title":"J. Clin. Endocrinol. Metabolism"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1210\/jc.2014-2700","article-title":"Acromegaly: An endocrine society clinical practice guideline","volume":"99","author":"Katznelson","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"R89","DOI":"10.1530\/EJE-17-1006","article-title":"Personalized medicine in the treatment of acromegaly","volume":"178","author":"Kasuki","year":"2018","journal-title":"Eur. J. Endocrinol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Pichler, R., Kalev, O., Tomancok, B., Sonnberger, M., Ehrlich, D., and Hodolic, M. (2021). Somatostatin receptor subtype expression in patients with acromegaly and complicated clinical course. Diagnostics, 11.","DOI":"10.3390\/diagnostics11061050"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1210\/clinem\/dgac512","article-title":"Predictive Factors of Somatostatin Receptor Ligand Response in Acromegaly\u2014A Prospective Study","volume":"107","author":"Ilie","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1007\/s11102-012-0445-1","article-title":"Growth hormone granulation pattern and somatostatin receptor subtype 2A correlate with postoperative somatostatin receptor ligand response in acromegaly: A large single center experience","volume":"16","author":"Brzana","year":"2013","journal-title":"Pituitary"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1111\/jcmm.16173","article-title":"Predictive and prognostic significance of tumour subtype, SSTR1-5 and e-cadherin expression in a well-defined cohort of patients with acromegaly","volume":"25","author":"Soukup","year":"2021","journal-title":"J. Cell Mol. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3088","DOI":"10.1111\/jcmm.13851","article-title":"E-cadherin expression is associated with somatostatin analogue response in acromegaly","volume":"23","author":"Dios","year":"2019","journal-title":"J. Cell Mol. Med."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Mendes, G., Haag, T., Trott, G., Rech, C., Ferreira, N., Oliveira, M., Kohek, M., and Pereira-Lima, J. (2018). Expression of E-cadherin, Slug and NCAM and its relationship to tumor invasiveness in patients with acromegaly. Braz. J. Med. Biol. Res., 51.","DOI":"10.1590\/1414-431x20176808"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Puig-Domingo, M., Bernab\u00e9u, I., Pic\u00f3, A., Biagetti, B., Gil, J., Alvarez-Escol\u00e1, C., Jord\u00e0, M., Marques-Pamies, M., Soldevila, B., and G\u00e1lvez, M.-A. (2021). Pasireotide in the Personalized Treatment of Acromegaly. Front. Endocrinol., 12.","DOI":"10.3389\/fendo.2021.648411"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1210\/jc.2018-01524","article-title":"Pasireotide Responsiveness in Acromegaly Is Mainly Driven by Somatostatin Receptor Subtype 2 Expression","volume":"104","author":"Muhammad","year":"2018","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s11060-024-04620-7","article-title":"Immunological signatures and predictive biomarkers for first-generation somatostatin receptor ligand resistance in Acromegaly","volume":"167","author":"Luo","year":"2024","journal-title":"J. Neurooncol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Berton, A.M., Prencipe, N., Bertero, L., Baldi, M., Bima, C., Corsico, M., Bianchi, A., Mantovani, G., Ferra\u00f9, F., and Sartorato, P. (2023). Resistance to Somatostatin Analogs in Italian Acromegaly Patients: The MISS Study. J. Clin. Med., 12.","DOI":"10.3390\/jcm12010025"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"6290","DOI":"10.1210\/jc.2005-0998","article-title":"The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly","volume":"90","author":"Bhayana","year":"2005","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"101354","DOI":"10.1016\/j.ghir.2020.101354","article-title":"Efficacy and predictors of short-term first-generation somatostatin analog presurgical treatment in acromegaly: A hospital-based study of 237 cases","volume":"55","author":"Shen","year":"2020","journal-title":"Growth Horm. IGF Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"101893","DOI":"10.1016\/j.beem.2024.101893","article-title":"Predictors of biochemical response to somatostatin receptor ligands in acromegaly","volume":"38","author":"Marazuela","year":"2024","journal-title":"Best Pr. Res. Clin. Endocrinol. Metab."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1530\/EJE-10-0586","article-title":"Relationship between cytokeratin staining patterns and clinico-pathological features in somatotropinomae","volume":"163","author":"Bakhtiar","year":"2010","journal-title":"Eur. J. Endocrinol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1530\/EJE-12-0864","article-title":"Granulation pattern, but not GSP or GHR mutation, is associated with clinical characteristics in somatostatin-na\u00efve patients with somatotroph adenomas","volume":"168","author":"Larkin","year":"2013","journal-title":"Eur. J. Endocrinol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1210\/clinem\/dgad673","article-title":"The Multibiomarker Acro-TIME Score Predicts fg-SRLs Response: Preliminary Results of a Retrospective Acromegaly Cohort","volume":"109","author":"Chiloiro","year":"2023","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1530\/EJE-13-0134","article-title":"Molecular and functional properties of densely and sparsely granulated GH-producing pituitary adenomas","volume":"169","author":"Mayr","year":"2013","journal-title":"Eur. J. Endocrinol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Dehghani, M., Davoodi, Z., Bidari, F., Moghaddam, A.M., Khalili, D., Bahrami-Motlagh, H., Jamali, E., Alamdari, S., Hosseinpanah, F., and Hedayati, M. (2021). Association of different pathologic subtypes of growth hormone producing pituitary adenoma and remission in acromegaly patients: A retrospective cohort study. BMC Endocr. Disord., 21.","DOI":"10.1186\/s12902-021-00850-2"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.humpath.2013.08.007","article-title":"Expression of somatostatin receptors, SSTR2A and SSTR 5, in 108 endocrine pituitary tumors using immunohistochemical detection with new specific monoclonal antibodies","volume":"45","author":"Chinezu","year":"2014","journal-title":"Hum. Pathol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s42000-021-00327-w","article-title":"Differences in somatostatin receptor subtype expression in patients with acromegaly: New directions for targeted therapy?","volume":"21","author":"Rass","year":"2022","journal-title":"Hormones"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1210\/clinem\/dgab726","article-title":"The Future of Somatostatin Receptor Ligands in Acromegaly","volume":"107","author":"Gadelha","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1530\/ERC-18-0565","article-title":"Molecular profiling for acromegaly treatment: A validation study","volume":"27","author":"Gil","year":"2020","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1210\/me.2009-0315","article-title":"Pasireotide and octreotide stimulate distinct patterns of sst2A somatostatin receptor phosphorylation","volume":"24","author":"Poll","year":"2010","journal-title":"Mol. Endocrinol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1210\/jc.2017-00135","article-title":"In vitro head-to-head comparison between octreotide and pasireotide in gh-secreting pituitary adenomas","volume":"102","author":"Gatto","year":"2017","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1210\/jc.2013-2480","article-title":"Pasireotide versus octreotide in acromegaly: A head-to-head superiority study","volume":"99","author":"Colao","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1530\/EJE-15-0832","article-title":"Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: An immunohistochemical study","volume":"174","author":"Iacovazzo","year":"2016","journal-title":"Eur. J. Endocrinol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Gil, J., Jord\u00e0, M., Soldevila, B., and Puig-Domingo, M. (2021). Epithelial\u2013Mesenchymal Transition in the Resistance to Somatostatin Receptor Ligands in Acromegaly. Front. Endocrinol., 12.","DOI":"10.3389\/fendo.2021.646210"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3756","DOI":"10.1007\/s00018-008-8281-1","article-title":"The cell-cell adhesion molecule E-cadherin","volume":"65","author":"Berx","year":"2008","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S1010-7940(03)00308-7","article-title":"Prognostic significance of E-cadherin and \u03b2-catenin in resected stage I non-small cell lung cancer","volume":"24","author":"Choi","year":"2003","journal-title":"Eur. J. Cardio-Thorac. Surg."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Lekva, T., Berg, J.P., Heck, A., Fougner, S.L., Olstad, O.K., Ringstad, G., Bollerslev, J., and Ueland, T. (2013). Attenuated RORC Expression in the Presence of EMT Progression in Somatotroph Adenomas following Treatment with Somatostatin Analogs Is Associated with Poor Clinical Recovery. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0066927"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Marques-Pamies, M., Gil, J., Sampedro-Nu\u00f1ez, M., Valassi, E., Biagetti, B., Gim\u00e9nez-Palop, O., Hern\u00e1ndez, M., Mart\u00ednez, S., Carrato, C., and Villar-Taibo, R. (2024). Personalized medicine in acromegaly: The ACROFAST study. J. Clin. Endocrinol. Metab., dgae444.","DOI":"10.1210\/clinem\/dgae444"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1210\/jc.2008-0126","article-title":"Prognostic significance of the Ki-67 labeling index in growth hormone-secreting pituitary adenomas","volume":"93","author":"Fusco","year":"2008","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1530\/EJE-13-0349","article-title":"Ki-67 is a predictor of acromegaly control with octreotide LAR independent of SSTR2 status and relates to cytokeratin pattern","volume":"169","author":"Kasuki","year":"2013","journal-title":"Eur. J. Endocrinol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"130","DOI":"10.4103\/1793-5482.142732","article-title":"The impact of immunohistochemical markers of Ki-67 and p53 on the long-term outcome of growth hormone-secreting pituitary adenomas: A cohort study","volume":"9","author":"Amirjmshidi","year":"2014","journal-title":"Asian J. Neurosurg."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1530\/EJE-20-0767","article-title":"Pegvisomant and Pasireotide LAR as second line therapy in acromegaly: Clinical effectiveness and predictors of response","volume":"184","author":"Chiloiro","year":"2021","journal-title":"Eur. J. Endocrinol."},{"key":"ref_44","unstructured":"(2022, November 05). Romanian National Health Insurance House \u201cCNAS\u201d Official Website, Therpeutic Protocols. Available online: https:\/\/cnas.ro\/protocoale-terapeutice\/."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"E66","DOI":"10.1210\/jc.2012-2609","article-title":"Immunoreactivity score using an anti-sst2A receptor monoclonal antibody strongly predicts the biochemical response to adjuvant treatment with somatostatin analogs in acromegaly","volume":"98","author":"Gatto","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/16\/8663\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:32:14Z","timestamp":1760110334000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/16\/8663"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,8]]},"references-count":45,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["ijms25168663"],"URL":"https:\/\/doi.org\/10.3390\/ijms25168663","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,8]]}}}